# CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

> **NCT06281405** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 192 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** PD-1 inhibitor
- **DRUG:** Capecitabine
- **RADIATION:** Short-course radiotherapy
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT06281405
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-28
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281405, "CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06281405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*